Bicycle Therapeutics falls on wider Q2 net loss

Bicycle Therapeutics

08/08/2025 13:07

** U.S.-listed shares of drug developer Bicycle Therapeutics BCYC.O fall 1.6% to $7.34 premarket

** Co reports Q2 net loss of $79 million vs net loss of $39.8 million a year ago

** Co says it is implementing a workforce reduction and taking other steps to optimize its operations to expand its cash runway

     ** Co had cash and cash equivalents of $721.5 million as of June 30 vs $879.5 million as of December 31, 2024

** Co says the decrease in cash and cash equivalents is due to cash used in operations, including increased cash payments for clinical program activities

** Expects total operational savings of about 30% over the course of the financial runway period; says these actions are expected to extend the financial runway into 2028- BCYC

** Up to last close, stock down 46.7% YTD

 (Reporting by Sneha S K)

 ((Sneha.SK@thomsonreuters.com))